CV
CapsoVision Inc
$
5.230
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.270
Open
5.270
VWAP
5.19
Vol
17.17K
Mkt Cap
244.99M
Low
5.0965
Amount
89.16K
EV/EBITDA(TTM)
--
Total Shares
46.84M
EV
227.20M
EV/OCF(TTM)
--
P/S(TTM)
--
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
Show More
2 Analyst Rating
14.72% Upside
Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
14.72% Upside
Current: 5.230
Low
5.00
Averages
6.00
High
7.00
14.72% Upside
Current: 5.230
Low
5.00
Averages
6.00
High
7.00
Roth Capital
NULL
to
Buy
initiated
$7
2025-11-04
Reason
Roth Capital
Price Target
$7
2025-11-04
initiated
NULL
to
Buy
Reason
Roth Capital resumed coverage of CapsoVision with a Buy rating and $7 price target. The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company's "best-in-class" device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision's small bowel artificial intelligence module as additional catalysts for the shares.
Roth Capital
Jason Wittes
Buy
initiated
$6
2025-07-28
Reason
Roth Capital
Jason Wittes
Price Target
$6
2025-07-28
initiated
Buy
Reason
Roth Capital analyst Jason Wittes initiated coverage of CapsoVision with a Buy rating and $6 price target. The firm believes the company is progressing advanced imaging and artificial intelligence implementation with its capsule endoscopy platform for gastrointestinal screening and diagnosis. CapsoVision is positioned for 19.5% growth in 2025 with its initial small bowel indication, and also recently submitted 510(k) approval for the much larger colon indication, the analyst tells investors in a research note. It sees this boosting revenue growth in 2026.
Benchmark
NULL -> Speculative Buy
initiated
$5
2025-07-28
Reason
Benchmark
Price Target
$5
2025-07-28
initiated
NULL -> Speculative Buy
Reason
Benchmark initiated coverage of CapsoVision with a Speculative Buy rating and $5 price target.
Benchmark
Speculative Buy
initiated
$5
2025-07-28
Reason
Benchmark
Price Target
$5
2025-07-28
initiated
Speculative Buy
Reason
As previously reported, Benchmark initiated coverage of CapsoVision with a Speculative Buy rating and $5 price target. The company's CapsoCam Plus for small bowel applications has been gaining market share with its differentiated features, notes the analyst, who sees the potential for additional long-term growth coming from international expansion and the ability to screen for multiple cancers simultaneously. The company will soon introduce AI-assisted image reading and a version of the product designed for the large intestine, the analyst noted.
See All Ratings
Valuation Metrics
The current forward P/E ratio for CapsoVision Inc (CV.O) is -10.16, compared to its 5-year average forward P/E of -8.78. For a more detailed relative valuation and DCF analysis to assess CapsoVision Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.78
Current PE
-10.16
Overvalued PE
-5.99
Undervalued PE
-11.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.97
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.50
Undervalued EV/EBITDA
-11.43
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
9.68
Current PS
0.00
Overvalued PS
15.12
Undervalued PS
4.24
Financials
Annual
Quarterly
FY2025Q3
3.54M
Total Revenue
FY2025Q3
-8.05M
Operating Profit
FY2025Q3
-7.92M
Net Income after Tax
FY2025Q3
-0.17
EPS - Diluted
FY2025Q3
-5.82M
Free Cash Flow
FY2025Q3
53.31
Gross Profit Margin - %
FY2025Q3
N/A
FCF Margin - %
FY2025Q3
-223.88
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CV News & Events
Events Timeline
2025-11-13 (ET)
2025-11-13
16:22:12
CapsoVision announces Q3 earnings per share of 17 cents, compared to a loss of $2.79 in the same period last year.
2025-11-10 (ET)
2025-11-10
16:57:39
CapsoVision Files Application for Breakthrough Device Designation of CapsoCam with FDA
2025-11-03 (ET)
2025-11-03
08:06:34
CapsoVision names David Garcia as Senior Vice President of Finance
Sign Up For More Events
Sign Up For More Events
News
9.5
11-13NASDAQ.COMCapsoVision Reports Increased Q3 Loss Due to Rising Operating Expenses
3.0
10-30NASDAQ.COMEarnings Report Ahead of Market Opening for October 31, 2025: XOM, ABBV, CVX, LIN, AON, CL, CNI, D, IMO, GWW, CHTR, CVE
4.5
07-22NASDAQ.COMPre-Market Most Active for Jul 22, 2025 : OPEN, TSLL, REPL, SQQQ, OSCR, NVDA, QS, RXRX, BBAI, JOBY, NIO, CVX
Sign Up For More News
People Also Watch
AAPL
Apple Inc
271.490
USD
+1.97%
TSLA
Tesla Inc
391.090
USD
-1.05%
WMT
Walmart Inc
105.320
USD
-1.67%
MSFT
Microsoft Corp
472.120
USD
-1.32%
META
Meta Platforms Inc
594.250
USD
+0.87%
AMZN
Amazon.com Inc
220.690
USD
+1.63%
NVDA
NVIDIA Corp
178.880
USD
-0.97%
AVGO
Broadcom Inc
340.200
USD
-1.91%
ORCL
Oracle Corp
198.760
USD
-5.66%
XOM
Exxon Mobil Corp
117.080
USD
+0.05%
FAQ
What is CapsoVision Inc (CV) stock price today?
The current price of CV is 5.23 USD — it has decreased -1.88 % in the last trading day.
What is CapsoVision Inc (CV)'s business?
What is the price predicton of CV Stock?
What is CapsoVision Inc (CV)'s revenue for the last quarter?
What is CapsoVision Inc (CV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CapsoVision Inc (CV)'s fundamentals?
How many employees does CapsoVision Inc (CV). have?